I told you on August 6 to set your alarms for late August. Set them for 8:00 a.m. ET tomorrow.
The Event. Amylyx confirmed this morning that topline results from the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia (PBH) land on August 18, 2026, with a management conference call and webcast at 8:00 a.m. ET — before the market opens. That is the whole announcement. No data, no hint, no directional language. Just a time stamp on the binary.
The Reaction. AMLX has traded from $24.19 on August 6 to $21.43 — a -11.4% slide into the readout. Nothing about the drug changed. What changed is that the option premium got expensive and some of the event-driven money that rode the +59% run from May decided it would rather watch the coin flip than call it.
The Reality. This is the moment the entire thesis I laid out in the deep dive resolves into a number. Everything else — the fortified balance sheet, the cleared legal overhang, the tea leaves of commercial prep — is scenery. Tomorrow morning we find out whether the lock-and-key pharmacology survives contact with a double-blind placebo arm.
The announcement. Topline from LUCIDITY on August 18, 2026; call at 8:00 a.m. ET; webcast archived 90 days. That is the entirety of the new information.
The implication: Pre-market release with a same-morning call is the standard choreography for a company that wants the number digested before the open rather than dribbled into an intraday tape. It tells you nothing about the direction — companies release good and bad pivotal data on exactly this schedule. Anyone reading a positive omen into the timing is reading tea leaves that aren’t there.
The trial, restated precisely. n=78, randomized 3:2 to 90 mg avexitide subcutaneously once daily or placebo, across 21 U.S. sites. Primary endpoint: reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16 — the endpoint the FDA agreed to. Last patient completed the final double-blind visit before the August 6 update; database lock and unblinding were all that remained.
The implication: Execution risk was retired weeks ago. There is exactly one variable left.
The drawdown. -11.4% in seven trading sessions on zero news flow.
The implication: This looks like pre-event de-risking, not information leakage. Pivotal readouts routinely see this pattern — momentum holders who bought the run-up trimming rather than sitting through a print that can halve the equity in a single session. It cuts the amount of good news already in the price, which marginally improves the risk/reward versus $24.19, but it does not change the shape of the outcome distribution.
This is the part worth having in front of you before 8:00 a.m., because pivotal topline releases are written to be read fast and generously.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.